Iradimed CORP 8-K filings

Iradimed Corporation announced its second quarter 2026 financial results, reporting revenue of $20.5 million and declaring a quarterly cash dividend of $0.20 per share.

Iradimed Corporation stockholders re-elected all board members, ratified the independent auditor, and approved executive compensation at the 2026 Annual Meeting.

IRADIMED CORPORATION announced record fourth quarter and full year 2025 financial results, including significant revenue and EPS growth, and increased its quarterly cash dividend to $0.20 per share.

IRADIMED Corporation announced a special cash dividend of $0.50 per share, payable on December 30, 2025, reflecting strong financial performance and excess cash.

IRADIMED Corporation announced record third-quarter 2025 financial results, including a 16% revenue increase, and raised its full-year guidance, alongside declaring a quarterly cash dividend.

IRADIMED Corporation announced the retirement of director Anthony Vuoto and the appointment of medical technology innovator Joe Kiani to its Board of Directors.

IRADIMED CORPORATION announced record second quarter 2025 financial results, including a 14% revenue increase and an 18% rise in GAAP diluted EPS, leading to an upward revision of its full-year 2025 revenue and earnings guidance and the declaration of a $0.17 per share quarterly cash dividend.

Iradimed Corporation announced the results of its Annual Meeting of Stockholders held on June 19, 2025, where all five director nominees were elected, RSM US LLP was ratified as the independent auditor, and executive compensation was approved on an advisory basis.

IRADIMED Corporation announced today that it has received FDA 510(k) clearance for its advanced MRidium 3870 IV Infusion Pump System, reinforcing its unique position as the sole global supplier of non-magnetic MRI infusion pump devices.

IRADIMED CORPORATION reports record revenue for Q1 2025, declares a regular quarterly cash dividend, and reaffirms its full-year 2025 revenue and earnings guidance.

IRADIMED Corporation reports record revenue for Q4 2024 and the full year, accompanied by an increase in the quarterly cash dividend.

iRadimed announced record preliminary unaudited revenues for the fourth quarter and full-year 2024, with strong year-over-year and sequential growth.

IRADIMED Corporation announced record revenue for the third quarter of 2024, driven by strong domestic IV infusion pump sales, and raised its full-year earnings guidance.

IRADIMED Corporation announced record revenue of $17.9 million for the second quarter of 2024, a 11.2% increase year-over-year, and declared a $0.15 per share quarterly dividend.

Iradimed Corporation held its annual stockholders meeting on June 20, 2024, where stockholders voted on the election of directors, ratification of the company's accounting firm, and an advisory resolution on executive compensation.

IRADIMED Corporation will transfer its stock listing from the Nasdaq Capital Market to the Nasdaq Global Market effective June 14, 2024.

IRADIMED Corporation has extended its lease agreement for its manufacturing and headquarters facility in Winter Springs, Florida, by one year.

IRADIMED announced record revenue of $17.6 million for the first quarter of 2024, along with a quarterly cash dividend of $0.15 per share.

IRADIMED Corporation announced record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023, alongside significant increases in operating income and earnings per share.